Breaking News Instant updates and real-time market news.

FATE

Fate Therapeutics

$12.81

-0.775 (-5.71%)

18:34
11/11/18
11/11
18:34
11/11/18
18:34

Fate Therapeutics announces dose-escalation clinical data of FATE-NK100

Fate Therapeutics announced new clinical data for FATE-NK100, an investigational, first-in-class, allogeneic donor-derived natural killer cell cancer immunotherapy, and provided a regulatory update on the development of FT500, a universal, off-the-shelf NK cell product candidate derived from a master induced pluripotent stem cell line, on November 10, 2018. Twenty heavily pre-treated subjects, each presenting with progressive disease at the time of enrollment, have been treated with FATE-NK100 in the dose-escalation phases of three Phase 1 clinical trials. As of a October 22, 2018 data cutoff, one-month follow-up data were available on fourteen subjects, with clinical benefit indicated in seven of these fourteen subjects: In the DIMENSION study for the treatment of advanced solid tumors, one subject at the second dose level and two subjects at the third dose level treated with a single intravenous infusion of FATE-NK100 in the monotherapy regimen had stable disease at one month. These two subjects at the third dose level were each subsequently treated with a second dose of FATE-NK100 and remain on study with ongoing disease control. The study is currently enrolling at the third dose level in the monotherapy regimen, at the second dose level in the cetuximab combination regimen and at the run-in dose level in the trastuzumab combination regimen. In the APOLLO study for the treatment of recurrent ovarian cancer, one subject treated with a single intraperitoneal infusion of FATE-NK100 at the second dose level had stable disease at one month. The subject was subsequently treated with a second dose of FATE-NK100 and maintained disease control for 6.2 months. The study is currently enrolling at the third dose level. In the VOYAGE study for the treatment of refractory or relapsed acute myelogenous leukemia, all three subjects treated with a single intravenous infusion of FATE-NK100 at the second dose level showed complete clearance of leukemic blasts in the bone marrow and achieved a morphologic leukemia-free state at Day 14 following treatment. Each of these three subjects received a single dose of FATE-NK100 only, and the anti-leukemic response in each of these subjects was transient. The study is currently enrolling at the second dose level. No dose limiting toxicities related to FATE-NK100 were reported. One serious adverse event related to FATE-NK100 was reported in the APOLLO study. In addition, the company announced that adventitious agents testing of the master iPSC bank for the clinical production of FT500, a universal, off-the-shelf NK cell product candidate, has been completed. The FT500 master iPSC bank was found to be free of adventitious agents as determined by in vivo and in vitro testing. The company has submitted these results to the U.S. Food and Drug Administration in furtherance of the agency's review of the company's FT500 Investigational New Drug application. Upon allowance by the FDA of the FT500 IND, the company plans to initiate Phase 1 clinical testing of FT500 as a monotherapy and in combination with checkpoint inhibitor therapy for the treatment of advanced solid tumors. This first-in-human study is expected to evaluate the safety and tolerability of multiple doses of FT500 in multiple dosing cycles.

  • 27

    Nov

  • 30

    Nov

  • 01

    Dec

FATE Fate Therapeutics
$12.81

-0.775 (-5.71%)

09/18/18
WELS
09/18/18
NO CHANGE
WELS
Fate Therapeutics platform validated with Ono deal, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Fate Therapeutics after the company announced a deal with Ono Pharmaceuticals for induced pluripotent stem cell derived CAR T Therapeutics. The deal validates Fate's iPSC platform, should increase confidence in near term investigational new drug application clearance and provides support for its accelerating pipeline development, Birchenough tells investors in a research note. He reiterates an Outperform rating on Fate Therapeutics.
09/18/18
PIPR
09/18/18
NO CHANGE
Target $25
PIPR
Overweight
Fate Therapeutics price target raised to $25 from $20 at Piper Jaffray
After Fate Therapeutics announced a collaboration with ONO Pharmaceutical for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates, Piper Jaffray analyst Edward Tenthoff said he likes the deal as it expands Fate's iPSC CAR-T pipeline while also giving the company $70M in near-term funding. Following the collaboration pact, Tenthoff increased his price target on Fate shares to $25 and reiterated an Overweight rating.
09/25/18
PIPR
09/25/18
NO CHANGE
Target $23
PIPR
Overweight
Fate Therapeutics price target lowered to $23 from $25 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Fate Therapeutics to $23 to account for dilution from the equity issuance. He estimates Fate now holds proforma cash of $223M to advance and expand its clinical pipeline of off-the-shelf Natural Killer cell and CAR-T therapies. The analyst reiterates an Overweight rating on the shares.
11/05/18
JEFF
11/05/18
INITIATION
Target $17
JEFF
Buy
Fate Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Fate Therapeutics with a Buy rating and $17 price target. Natural killer cells possess advantageous cytotoxic properties distinct from T cells, and have demonstrated clinical efficacy against select cancer types, Amin tells investors in a research note. The analyst says Fate "offers a unique and potentially disruptive approach."

TODAY'S FREE FLY STORIES

22:55
01/22/19
01/22
22:55
01/22/19
22:55
General news
Bank of Japan held policy steady »

Bank of Japan held policy…

COP

ConocoPhillips

$65.69

-2.21 (-3.25%)

, SNP

Sinopec

$77.78

-1.96 (-2.46%)

21:01
01/22/19
01/22
21:01
01/22/19
21:01
Periodicals
Breaking Periodicals news story on ConocoPhillips, Sinopec »

Sinopec and…

COP

ConocoPhillips

$65.69

-2.21 (-3.25%)

SNP

Sinopec

$77.78

-1.96 (-2.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 28

    May

ALPN

Alpine Immune Sciences

$5.79

(0.00%)

20:50
01/22/19
01/22
20:50
01/22/19
20:50
Hot Stocks
Alpine Immune Sciences CEO buys 191K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LW

Lamb Weston

$70.75

-0.145 (-0.20%)

20:36
01/22/19
01/22
20:36
01/22/19
20:36
Upgrade
Lamb Weston rating change at Stifel »

Lamb Weston upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$115.15

-1.675 (-1.43%)

, UTX

United Technologies

$111.23

-2.7 (-2.37%)

20:25
01/22/19
01/22
20:25
01/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KMB

Kimberly-Clark

$115.15

-1.675 (-1.43%)

UTX

United Technologies

$111.23

-2.7 (-2.37%)

ABT

Abbott

$71.56

0.13 (0.18%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$35.16

-1.05 (-2.90%)

PG

Procter & Gamble

$90.50

-0.89 (-0.97%)

PGR

Progressive

$63.18

-1.24 (-1.92%)

APH

Amphenol

$81.06

-1.41 (-1.71%)

SYF

Synchrony

$26.55

0.27 (1.03%)

WAT

Waters

$203.52

-3.315 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 27

    Jan

  • 30

    Jan

  • 11

    Feb

  • 18

    Feb

  • 03

    Mar

  • 28

    May

TXRH

Texas Roadhouse

$66.00

-1 (-1.49%)

20:23
01/22/19
01/22
20:23
01/22/19
20:23
Downgrade
Texas Roadhouse rating change at Stifel »

Texas Roadhouse…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$83.34

-2.27 (-2.65%)

, JBLU

JetBlue

$17.36

-0.24 (-1.36%)

19:49
01/22/19
01/22
19:49
01/22/19
19:49
Hot Stocks
Normal operations at Newark Airport have resumed after reported drone activity »

Newark International…

UAL

United Continental

$83.34

-2.27 (-2.65%)

JBLU

JetBlue

$17.36

-0.24 (-1.36%)

AAL

American Airlines

$32.75

-1.21 (-3.56%)

LUV

Southwest

$50.54

-1.04 (-2.02%)

DAL

Delta Air Lines

$47.10

-1 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 04

    Mar

PLL

Piedmont Lithium

$7.60

(0.00%)

19:35
01/22/19
01/22
19:35
01/22/19
19:35
Hot Stocks
Piedmont Lithium initiates 25K meter drill program »

Piedmont Lithium Limited…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSBC

Great Southern Bancorp

$49.85

-0.7 (-1.38%)

19:34
01/22/19
01/22
19:34
01/22/19
19:34
Earnings
Great Southern Bancorp reports preliminary Q4 EPS $1.21, consensus $1.12 »

Reports Q4 NII $44.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 13

    Feb

  • 14

    Feb

BAYRY

Bayer

$0.00

(0.00%)

19:08
01/22/19
01/22
19:08
01/22/19
19:08
Periodicals
Bayer requests that CA judge limit evidence in Roundup trial, Reuters says »

Bayer's Monsanto has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$413.28

-6.01 (-1.43%)

19:07
01/22/19
01/22
19:07
01/22/19
19:07
Hot Stocks
BlackRock CEO sells 30.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

  • 11

    Feb

EHTH

eHealth

$45.38

-0.85 (-1.84%)

, ARAY

Accuray

$3.97

0.09 (2.32%)

19:01
01/22/19
01/22
19:01
01/22/19
19:01
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

EHTH

eHealth

$45.38

-0.85 (-1.84%)

ARAY

Accuray

$3.97

0.09 (2.32%)

NAVI

Navient

$10.87

-0.05 (-0.46%)

IBM

IBM

$122.34

-1.49 (-1.20%)

CNMD

Conmed

$66.62

-0.03 (-0.05%)

PUMP

ProPetro Holding

$14.96

-0.49 (-3.17%)

AMTD

TD Ameritrade

$54.96

-0.38 (-0.69%)

TBNK

Territorial Bancorp

$26.90

-0.26 (-0.96%)

APHA

Aphria

$7.07

0.41 (6.16%)

TSE

Trinseo

$48.54

-2.78 (-5.42%)

COF

Capital One

$83.38

-1.62 (-1.91%)

QUOT

Quotient Technology

$10.99

-0.55 (-4.77%)

IBKR

Interactive Brokers

$51.92

-2.82 (-5.15%)

PTCT

PTC Therapeutics

$33.08

-1.245 (-3.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 10

    Feb

  • 11

    Feb

  • 13

    Feb

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 18

    May

  • 23

    Jan

  • 25

    Jan

APHA

Aphria

$7.07

0.41 (6.16%)

18:55
01/22/19
01/22
18:55
01/22/19
18:55
Hot Stocks
Green Growth files offer to acquire Aphria »

Green Growth Brands Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$33.69

0.24 (0.72%)

18:42
01/22/19
01/22
18:42
01/22/19
18:42
Hot Stocks
Logitech CEO says 'we had a very strong quarter' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

WBA

Walgreens Boots Alliance

$71.59

-0.81 (-1.12%)

18:39
01/22/19
01/22
18:39
01/22/19
18:39
Periodicals
Walgreens to pay $269.2M to resolve U.S. fraud suits, Reuters reports »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

SMBC

Southern Missouri Bancorp

$32.22

-0.29 (-0.89%)

18:35
01/22/19
01/22
18:35
01/22/19
18:35
Earnings
Southern Missouri Bancorp sees Q2 adjusted EPS 81c, consensus 72c »

Southern Missouri…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Z

Zillow

$31.41

-2.52 (-7.43%)

18:32
01/22/19
01/22
18:32
01/22/19
18:32
Hot Stocks
Zillow's StreetEasy unveils new Listing Tools platform »

StreetEasyunveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$32.44

-0.71 (-2.14%)

, VIAB

Viacom

$29.22

-0.87 (-2.89%)

18:25
01/22/19
01/22
18:25
01/22/19
18:25
Hot Stocks
Viacom to acquire Pluto TV for $340M in cash »

Viacom Inc. announced…

VIA

Viacom

$32.44

-0.71 (-2.14%)

VIAB

Viacom

$29.22

-0.87 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

GOOG

Alphabet

$1,070.72

-27.53 (-2.51%)

, GOOGL

Alphabet Class A

$1,078.68

-28.24 (-2.55%)

18:23
01/22/19
01/22
18:23
01/22/19
18:23
Periodicals
Google spent company-record $21.2M on U.S. lobbying in 2018, Reuters says »

Alphabet's Google…

GOOG

Alphabet

$1,070.72

-27.53 (-2.51%)

GOOGL

Alphabet Class A

$1,078.68

-28.24 (-2.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

VIA

Viacom

$32.44

-0.71 (-2.14%)

, VIAB

Viacom

$29.22

-0.87 (-2.89%)

18:16
01/22/19
01/22
18:16
01/22/19
18:16
Periodicals
Viacom to buy Pluto TV for $340M in cash, THR reports »

Viacom will pay $340M in…

VIA

Viacom

$32.44

-0.71 (-2.14%)

VIAB

Viacom

$29.22

-0.87 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

AZZ

AZZ Inc.

$45.09

-0.67 (-1.46%)

18:13
01/22/19
01/22
18:13
01/22/19
18:13
Earnings
AZZ Inc. sees FY20 EPS $2.25-$2.75, consensus $2.54 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.80

-3.46 (-1.14%)

18:13
01/22/19
01/22
18:13
01/22/19
18:13
Hot Stocks
Elon Musk says Tesla Sentry Mode 'coming soon' for cars with Enhanced Autopilot »

Tesla CEO Elon Musk said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

NCOM

National Commerce

$39.07

-0.03 (-0.08%)

18:01
01/22/19
01/22
18:01
01/22/19
18:01
Earnings
National Commerce reports Q4 EPS 51c, consensus 68c »

Reports Q4 NII $43.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$122.34

-1.49 (-1.20%)

18:01
01/22/19
01/22
18:01
01/22/19
18:01
Hot Stocks
IBM says Red Hat acquisition will help accelerate leadership in hybrid cloud »

Says tax was a headwind…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

UAL

United Continental

$83.34

-2.27 (-2.65%)

17:57
01/22/19
01/22
17:57
01/22/19
17:57
Periodicals
United Continental says FAA initiated ground stop for all Newark traffic 

Reported by Bloomberg.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.